why choose us

First received: October 24, 2023

Clinical Trial: A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Chikungunya Virus Infection

Study Type: INTERVENTIONAL


Official Title: A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Chi

Brief Summary: This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.At least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two VLA1553 dose groups (n=120 each) or control (n=60).

Read more